Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including Carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Castanheira, Mariana ^a   Huband, Michael D ^a   Mendes, Rodrigo E ^a   Flamm, Robert K ^a  

^a JMI LABORATORIES   (United States)

Author keywords

CRE; KPC producers; Meropenem vaborbactam

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; MEROPENEM; THIENAMYCIN DERIVATIVE;

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATION; DRUG EFFECT; GENETICS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 85028338750     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00567-17     Document Type: Article

References (18)

1. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25:450–470. https://doi.org/10.1128/CMR.05041-11.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. https://doi.org/10.1086/595011.
3. Livermore DM. 2009. Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29–i36. https://doi.org/10.1093/jac/dkp255.
4. Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568–585. https://doi.org/10.1016/j.ijantimicag.2015.03.001.
5. Pitout JD, Nordmann P, Poirel L. 2015. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. https://doi.org/10.1128/AAC.01019-15.
6. Landman D, Babu E, Shah N, Kelly P, Olawole O, Backer M, Bratu S, Quale J. 2012. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother 67: 1427–1431. https://doi.org/10.1093/jac/dks063.
7. Castanheira M, Farrell SE, Wanger A, Rolston KV, Jones RN, Mendes RE. 2013. Rapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineages. Microb Drug Resist 19:295–297. https://doi.org/10.1089/mdr.2012.0238.
8. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682–3692. https://doi.org/10.1021/acs.jmedchem.5b00127.
9. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. 2015. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856–4860. https://doi.org/10.1128/AAC.00843-15.
10. Livermore DM, Mushtaq S. 2013. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 68: 1825–1831. https://doi.org/10.1093/jac/dkt118.
11. Tarazi Z, Sabet M, Rubio-Aparicio D, Nolan T, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. 2014. Efficacy of simulated human exposures of carbavance (meropenem-RPX7009) against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model, abstr F-959. Abstr 54th Int Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
12. CLSI. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
13. CLSI. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
14. EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0, January 2016. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table .pdf.
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
16. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 57:6305–6310. https://doi.org/10.1128/AAC.01802-13.
17. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09). J Antimicrob Chemother 66:1409–1411. https://doi.org/10.1093/jac/dkr081.
18. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835–1846. https://doi.org/10.1128/AAC.00826-13.